Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1 The study published in Nature Communications suggests lige…
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of ca…
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), for all of the outstandin…
At Novartis, we celebrate life and recognize moments that matter. One of the most life-changing moments our associates experience is becoming a parent and welcoming new life into their lives. In July 2019, we introduced equal paid parental leave of a…
Dear SMA Community,Since its U.S. approval, AveXis has had increasing demand from families outside of the U.S. for access to AVXS-101. While we are pursuing registration in close to three dozen countries, we have heard the many requests from the SMA co…
Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across treatment groupsBasel, Switzerland, December 16, 2019 – Novartis t…
In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retinal fluid at week 16 and year o…
MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30% Overall survival benefit for Kisqali plus fulvestr…
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy adverse events for patients with DLBCL, specifically rates o…
It’s the dream of every medical scientist: when the years of relentless effort, minor victories, setbacks and challenges of research finally yield a breakthrough that may one day change the way patients are treated. Catherine Sabatos-Peyton, Director, …
